Search research articles
Contact Us
Filters
Showing results (81-90 of 222) with videos related to
Page
of 23
Sort By:
Archives of Dermatological Research
|
May 28, 2009
Humanized anti-CD2 monoclonal antibody treatment of plaque psoriasis: efficacy and pharmacodynamic results of two randomized, double-blind, placebo-controlled studies of intravenous and subcutaneous siplizumab
Robert Bissonnette, Richard G Langley, Kim Papp, et al.
Cutis
|
December 2, 2024
Treat-to-Target Outcomes With Tapinarof Cream 1% in Phase 3 Trials for Plaque Psoriasis
April W Armstrong, Robert Bissonnette, Raj Chovatiya, et al.
Plos One
|
May 7, 2016
Based on Molecular Profiling of Gene Expression, Palmoplantar Pustulosis and Palmoplantar Pustular Psoriasis Are Highly Related Diseases that Appear to Be Distinct from Psoriasis Vulgaris
Robert Bissonnette, Mayte Suárez-Fariñas, Xuan Li, et al.
The Journal of Investigative Dermatology
|
May 18, 2016
The Spectrum of Mild to Severe Psoriasis Vulgaris Is Defined by a Common Activation of IL-17 Pathway Genes, but with Key Differences in Immune Regulatory Genes
Jaehwan Kim, Robert Bissonnette, Jongmi Lee, et al.
The New England Journal of Medicine
|
February 13, 2023
Phase 2 Trial of Difelikefalin in Notalgia Paresthetica
Brian S Kim, Robert Bissonnette, Kristine Nograles, et al.
Journal of Cutaneous Medicine and Surgery
|
January 8, 2010
The AWARE study: methodology and baseline characteristics
Robert Bissonnette, Gordon Searles, Ian Landells, et al.
The Journal of Dermatological Treatment
|
February 1, 2024
Ruxolitinib cream monotherapy demonstrates rapid improvement in the extent and signs of mild to moderate atopic dermatitis across head and neck and other anatomic regions in adolescents and adults: pooled results from 2 phase 3 studies
Eric L Simpson, Robert Bissonnette, Zelma C Chiesa Fuxench, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
January 25, 2023
Efficacy and safety of etrasimod, a sphingosine 1-phosphate receptor modulator, in adults with moderate-to-severe atopic dermatitis (ADVISE)
Jonathan I Silverberg, Robert Bissonnette, Leon Kircik, et al.
Archives of Dermatological Research
|
March 20, 2024
Validation of the Investigator Global Assessment of Chronic Hand Eczema (IGA-CHE): a new clinician reported outcome measure of CHE severity
Jonathan I Silverberg, Tove Agner, Keith Baranowski, et al.
American Journal of Clinical Dermatology
|
November 1, 2025
Correction to: Summary of Research: Efficacy and Safety of Delgocitinib Cream in Adults with Moderate to Severe Chronic Hand Eczema (DELTA 1 and DELTA 2): Results from Multicentre, Randomised, Controlled, Double‑Blind, Phase 3 Trials
Robert Bissonnette, Fatima Albreiki, Benjamin D Ehst, et al.
Page
of 23
Search research articles
Search
Showing results (81-90 of 222) with videos related to
Sort By:
Page
of 23
Archives of Dermatological Research
|
May 28, 2009
Humanized anti-CD2 monoclonal antibody treatment of plaque psoriasis: efficacy and pharmacodynamic results of two randomized, double-blind, placebo-controlled studies of intravenous and subcutaneous siplizumab
Robert Bissonnette, Richard G Langley, Kim Papp, et al.
Cutis
|
December 2, 2024
Treat-to-Target Outcomes With Tapinarof Cream 1% in Phase 3 Trials for Plaque Psoriasis
April W Armstrong, Robert Bissonnette, Raj Chovatiya, et al.
Plos One
|
May 7, 2016
Based on Molecular Profiling of Gene Expression, Palmoplantar Pustulosis and Palmoplantar Pustular Psoriasis Are Highly Related Diseases that Appear to Be Distinct from Psoriasis Vulgaris
Robert Bissonnette, Mayte Suárez-Fariñas, Xuan Li, et al.
The Journal of Investigative Dermatology
|
May 18, 2016
The Spectrum of Mild to Severe Psoriasis Vulgaris Is Defined by a Common Activation of IL-17 Pathway Genes, but with Key Differences in Immune Regulatory Genes
Jaehwan Kim, Robert Bissonnette, Jongmi Lee, et al.
The New England Journal of Medicine
|
February 13, 2023
Phase 2 Trial of Difelikefalin in Notalgia Paresthetica
Brian S Kim, Robert Bissonnette, Kristine Nograles, et al.
Journal of Cutaneous Medicine and Surgery
|
January 8, 2010
The AWARE study: methodology and baseline characteristics
Robert Bissonnette, Gordon Searles, Ian Landells, et al.
The Journal of Dermatological Treatment
|
February 1, 2024
Ruxolitinib cream monotherapy demonstrates rapid improvement in the extent and signs of mild to moderate atopic dermatitis across head and neck and other anatomic regions in adolescents and adults: pooled results from 2 phase 3 studies
Eric L Simpson, Robert Bissonnette, Zelma C Chiesa Fuxench, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
January 25, 2023
Efficacy and safety of etrasimod, a sphingosine 1-phosphate receptor modulator, in adults with moderate-to-severe atopic dermatitis (ADVISE)
Jonathan I Silverberg, Robert Bissonnette, Leon Kircik, et al.
Archives of Dermatological Research
|
March 20, 2024
Validation of the Investigator Global Assessment of Chronic Hand Eczema (IGA-CHE): a new clinician reported outcome measure of CHE severity
Jonathan I Silverberg, Tove Agner, Keith Baranowski, et al.
American Journal of Clinical Dermatology
|
November 1, 2025
Correction to: Summary of Research: Efficacy and Safety of Delgocitinib Cream in Adults with Moderate to Severe Chronic Hand Eczema (DELTA 1 and DELTA 2): Results from Multicentre, Randomised, Controlled, Double‑Blind, Phase 3 Trials
Robert Bissonnette, Fatima Albreiki, Benjamin D Ehst, et al.
Page
of 23